A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P4502C9

被引:126
作者
Tham, Lai-San
Goh, Boon-Cher
Nafziger, Anne
Guo, Jia-Yi
Wang, Ling-Zhi
Soong, Richie
Lee, Soo-Chin
机构
[1] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore 119074, Singapore
[2] Oncol Res Inst, Singapore, Singapore
[3] Ordway Res Inst, Drug Dev Ctr, Albany, NY USA
关键词
D O I
10.1016/j.clpt.2006.06.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Because of the unique lack of genetic diversity despite the multiethnicity in the Asian population, we hypothesize that single-nucleotide polymorphisms in cytochrome P450 (CYP) 2C9 (CYP2C9*3) and vitamin Kepoxide reductase complex subunit 1 (VKORC1) at position 381, used to infer VKORC1 haplotype in combination with demographic factors, can accurately predict warfarin doses. The aims of this study were to derive a pharmacogenetics-based dosing algorithm by use of retrospective information and to validate it through a data-splitting method in a separate cohort of equal size. Methods. We used 215 records of warfarin patients recruited into a CYP2C9/VKORC1 genotyping study to perform this analysis. Univariate analyses for individual predictors, including age, weight, gender, serum albumin concentration, ethnic group, international normalized ratio, and CYP2C9 and VKORC1 381 genotypes, were conducted to select variables with P < .1 for further inclusion into the multivariate regression analysis. In the final model only predictors reaching a statistical significance of P < .05 were retained. Results. Data from 107 subjects undergoing maintenance warfarin therapy with an international normalized ratio stabilized between 2 and 3 were used to derive the final model, as an exponential function of age, weight, CYP2C9*3 allele, and VKORC1 381 CC and TC genotypes, and this model accounted for 60.2% of the variability in daily warfarin dose requirement. The model was validated in a separate cohort of 108 subjects and showed a mean underestimation of 0.23 +/- 1.21 mg/d. Conclusion: Warfarin dose requirements in Asians can be accurately predicted by use of a combination of patient demographics and a simplified genotyping approach for single variants in CYP2C9 and VKORC1.
引用
收藏
页码:346 / 355
页数:10
相关论文
共 41 条
  • [21] Interindividual variability in sensitivity to warfarin - Nature or nurture?
    Loebstein, R
    Yonath, H
    Peleg, D
    Almog, S
    Rotenberg, M
    Lubetsky, A
    Roitelman, J
    Harats, D
    Halkin, H
    Ezra, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) : 159 - 164
  • [22] Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
    Mushiroda, T
    Ohnishi, Y
    Saito, S
    Takahashi, A
    Kikuchi, Y
    Saito, S
    Shimomura, H
    Wanibuchi, Y
    Suzuki, T
    Kamatani, N
    Nakamura, Y
    [J]. JOURNAL OF HUMAN GENETICS, 2006, 51 (03) : 249 - 253
  • [23] Multicentre randomised study of computerised anticoagulant dosage
    Poller, L
    Shiach, CR
    MacCallum, PK
    Johansen, AM
    Münster, AM
    Magalhaes, A
    Jespersen, J
    [J]. LANCET, 1998, 352 (9139) : 1505 - 1509
  • [24] A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin
    Rettie, AE
    Haining, RL
    Bajpai, M
    Levy, RH
    [J]. EPILEPSY RESEARCH, 1999, 35 (03) : 253 - 255
  • [25] Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
    Rieder, MJ
    Reiner, AP
    Gage, BF
    Nickerson, DA
    Eby, CS
    McLeod, HL
    Blough, DK
    Thummel, KE
    Veenstra, DL
    Rettie, AE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) : 2285 - 2293
  • [26] The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:: proposal for a new dosing regimen
    Sconce, EA
    Khan, TI
    Wynne, HA
    Avery, P
    Monkhouse, L
    King, BP
    Wood, P
    Kesteven, P
    Daly, AK
    Kamali, F
    [J]. BLOOD, 2005, 106 (07) : 2329 - 2333
  • [27] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
    Scordo, MG
    Pengo, V
    Spina, E
    Dahl, ML
    Gusella, M
    Padrini, R
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) : 702 - 710
  • [28] The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin
    Tabrizi, AR
    Zehnbauer, BA
    Borecki, IB
    McGrath, SD
    Buchman, TG
    Freeman, BD
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2002, 194 (03) : 267 - 273
  • [29] CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin:: Similarities yet differences
    Takahashi, H
    Wilkinson, GR
    Padrini, R
    Echizen, H
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) : 376 - 380
  • [30] Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients
    Takahashi, H
    Wilkinson, GR
    Caraco, Y
    Muszkat, M
    Kim, RB
    Kashima, T
    Kimura, S
    Echizen, H
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (03) : 253 - 263